Poliomyelitis (polio) is a highly infectious viral disease that can involve the nervous system and can cause paralysis. Polio is most common in infants and children but can occur in adults. Because of widespread polio vaccination, the disease is now very rare in developed countries but still occurs in developing countries where vaccination coverage is not complete. The October 13, 2004, issue of JAMA includes an article about changing recommendations for giving the polio vaccine in the United States.
Grahic Jump Location
The poliovirus usually enters the body through the mouth from hands that have contacted the virus from an infected person.
The virus can be found in the throat and multiplies in the intestines.
The poliovirus can invade nerve cells that control muscles, including those involved with breathing.
Most people infected with the poliovirus have few, if any, symptoms.
Others have short-term symptoms that include headache, tiredness, fever, stiff neck and back, and muscle pain.
If the nervous system becomes infected, permanent paralysis can occur, usually of the legs and less commonly involving the breathing muscles, which may require artificial ventilation.
Although there is no cure for polio, it can be prevented by giving the polio vaccine multiple times, ideally during childhood. There are 2 types of polio vaccine:
Oral polio vaccine (OPV) is taken by mouth and contains weakened but live polio virus.
Inactivated polio vaccine (IPV) contains killed poliovirus and is given as an injection.
Oral polio vaccine can rarely cause polio and is no longer available in the United States. Inactivated polio vaccine is thought not to be as good as OPV in preventing the spread of polio in a community. However, a person cannot get polio from IPV.
Before polio vaccine became available in the 1950s, thousands of cases occurred every year in the United States. The last case of polio originating in the United States (except for cases caused by OPV) was in 1979. To eliminate cases of polio acquired through OPV, the US national vaccination recommendations changed in 2000 to use exclusively IPV for vaccination against polio.
In 1988, a global initiative was launched to eradicate polio. Since the initiative was launched, the number of polio cases has dropped by more than 99%, from an estimated 350 000 cases worldwide in 1988 to 1919 cases in 2002. In the same period, the number of countries with significant numbers of polio cases dropped from 125 to 7. Countries that presently have the highest rates of polio include Afghanistan, Egypt, India, Niger, Nigeria, and Pakistan.
American Academy of Pediatrics 202/347-8600 http://www.aap.org
Centers for Disease Control and Preventionhttp://www.cdc.gov/nip/menus/vaccines.htm#polio
World Health Organization 202/974-3000 http://www.who.int/en/
To find this and other JAMA Patient Pages, go to the Patient Page link on JAMA 's Web site at http://www.jama.com. Many are available in English and Spanish.
Sources: American Academy of Pediatrics, Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health.
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. Any other print or online reproduction is subject to AMA approval. To purchase bulk reprints, call 718/946-7424.
VIRAL DISEASES
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.